Interpace's thyroid tests lift quarterly sales 18%; pancreatic test stays off the revenue line
Interpace Biosciences posted $10.4M in third-quarter revenue and positive adjusted EBITDA, but one-off charges produced a loss and its pancreatic test is not expected to sell before 2028.
17 Nov 2026 · Interpace Biosciences, Inc. IDXG · Company news
Interpace Biosciences now depends commercially on two thyroid tests. The company reported third-quarter 2026 revenue of $10.4M on 16 November, 18% higher than a year earlier. It credited ThyGeNEXT and ThyraMIR v2, whose combined test volume rose 7%.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Interpace Biosciences, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More EarningsAll →
Earnings
Prenetics widens H2 EBITDA loss guidance to $30-35M as IM8 spending rises
18 Nov 2026 · Prenetics Global Ltd PRE · Company news
Earnings
newcleo reports Q3 revenue of about €10M and €233.4M cash as PRECURSOR e-core completed
18 Nov 2026 · newcleo plc NWCL · Company news
Earnings
Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop
17 Nov 2026 · Iridex Corp IRIX · Company news
Earnings
Zentek reports C$15.2M six-month profit on impairment reversal; cash rises to C$13.6M
17 Nov 2026 · Zentek Ltd. ZTEKF · Company news
Earnings
Vivos Therapeutics regains Nasdaq equity compliance as Q3 revenue rises 24% sequentially
17 Nov 2026 · Vivos Therapeutics, Inc. VVOS · Company news
Earnings
Mesoblast reports US$115M first full-year Ryoncil sales and advances four late-stage programmes
17 Nov 2026 · Mesoblast Ltd MESO · Company news